by 
The angioedema treatment market is a highly consolidated therapeutic area comprising various drug types that provide treatment for conditions characterized by acute episodes of subcutaneous or submucosal edema. Selective bradykinin B2 receptor antagonists such as icatibant from Shire/Jerini/Takeda are the standard treatment options for acute angioedema attacks. However, their high costs and potential side effects limit widespread adoption.
The Global angioedema treatment market is estimated to be valued at US$ 470.4 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the angioedema treatment are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. The increasing prevalence of hereditary angioedema and growing awareness about available treatments represent major opportunities in the market. Advances in drug research and development have led to newer treatment options with improved safety and efficacy profiles such as plasma-derived C1 inhibitors and gene therapy.
Market Drivers
The angioedema treatment market is driven by rising incidences of hereditary and acquired angioedema globally. According to estimations, about 1 in 10,000 to 1 in 50,000 people in the United States have hereditary angioedema (HAE). Other key drivers include an increasing focus on developing prophylactic therapies with longer half-lives to provide sustained protection against attacks, growing healthcare expenditures in major markets, and rising awareness about available treatment options for HAE.
Current challenges in Angioedema Treatment Market
The Angioedema Treatment Market faces several challenges primarily related to the lack of safe and effective treatment options. Many existing drugs have serious side effects and issues related to drug resistance limit their long term use. Additionally, the exact pathogenesis behind many types of angioedema remains unknown making treatment development difficult. Other challenges include lack of approved drugs for treating recurrent angioedema attacks, unclear diagnosis in many cases and need for emergency treatment in acute attacks. Overall, the need for novel, targeted and well-tolerated treatment options dominates the current market landscape.
SWOT Analysis
Strength: Growing research and development activities for developing more targeted and safer drugs. Emergence of oral drugs reduced reliance on injectables.
Weakness: High treatment cost of newer therapies. Lack of drugs approved for self-administration in acute attacks.
Opportunity: Rising angioedema cases globally increased awareness and need for improved care. Market entry of biosimilars and generics will enhance access and reduce costs.
Threats: Safety issues and side effects of existing drugs. Lack of understanding on pathogenesis limits drug development. Risk of substituting generic drugs.
Geographical regions with market concentration
North America dominates the global Angioedema Treatment Market in terms of value, accounting for more than 35% share. This is owing to the high healthcare spending, presence of top manufacturers, and growing disease burden in the region. Europe holds the second largest share, supported by availability of reimbursements and wide acceptance of new treatment approaches.
Fastest growing region
The Asia Pacific region is estimated to witness the fastest growth over the forecast period in the global Angioedema Treatment Market. Factors such as increasing healthcare expenditure, rising prevalence of angioedema, growing awareness about available treatments, and expansion efforts by major players are driving the market growth in Asia Pacific. Additionally, low treatment cost and availability of generics enhances the market attractiveness in the region.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
